Exploratory Study on POL6326 in Stem Cell Mobilization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01105403
Recruitment Status : Completed
First Posted : April 16, 2010
Last Update Posted : April 23, 2014
Information provided by (Responsible Party):
Polyphor Ltd.

Brief Summary:
The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: POL6326 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma
Study Start Date : April 2009
Actual Primary Completion Date : February 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: CD34+ mobilisation for transplantation Drug: POL6326
IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
Other Name: not appicable

Primary Outcome Measures :
  1. To assess the ability of POL6326 to mobilise CD34+ hematopoietic stem cells in patients with primary multiple myeloma [ Time Frame: Up to four days ]

    Number of patients achieving the minimal number of CD34+ cells (≥2 x 10 mill/kg BW) collected during one to four cycles of apheresis which are considered necessary and safe to proceed with autotransplantation

    Number of apheresis cycles required to obtain the minimal number of CD34+ cells necessary for autotransplantation (≥2 x 10 mill/kg BW)

Secondary Outcome Measures :
  1. To evaluate the safety and pharmacokinetics of POL6326 in patients with multiple myeloma [ Time Frame: 2 months ]
  2. To determine the efficacy of POL6326 in reconstitution of immune system after transplantation [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Have multiple myeloma in Stage II or III, according to the criteria of Durie and Salmon.
  2. Male or female between 18 and 70 years of age, inclusive. Male and females capable of reproduction must agree to use adequate contraceptive measures (e.g. condom, intrauterine device, oral contraceptive) until 3 months after termination of treatment.
  3. Measurable disease, defined by one of the following:

    • Serum M protein ≥1.0 g/dL by protein electrophoresis
    • Quantifiable immunoglobulin levels and/or
    • urinary M protein excretion ≥200 mg/24 hours.
  4. All patients have undergone 3 cycles of chemotherapy, with the last dose of chemotherapy given 3 to 8 weeks before study entry.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 2.
  6. Life expectancy of >6 months.
  7. Have given their written informed consent to participate in the study

Exclusion Criteria:

  1. Have non-secretory myeloma and/or plasma cell leukaemia.
  2. History of other malignancies during the past 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma, or localised prostate carcinoma.
  3. Any other clinically significant medical conditions.
  4. History of cardiac disease NHYA classification ≥3.
  5. Insufficient bone marrow, liver and renal function as assessed by the following clinical laboratory evaluations:

    Haemoglobin <9.0 g/L. Absolute neutrophil count <1500/µL. Platelet count <50000/µL. Total bilirubin >1.5 x upper limit of normal (ULN). Alanine aminotransferase (ALT) and alkaline phosphatase (AP) >2.5 x ULN. Amylase and lipase >1.5 x ULN. Serum creatinine >2.0 x ULN. Prothrombin time (PT) and activated partial thrombo-plastin time (aPTT) >1.5 x ULN.

  6. Pregnant or lactating female patients.
  7. Known history of HIV infection or chronic hepatitis B or C infection.
  8. Receipt of immunotherapy, radiation therapy, or any investigational drug within 30 days of study drug administration.
  9. Prior radiotherapy to more than 3 vertebrae.
  10. Active serious bacterial or fungal infections; >grade 3 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
  11. Receipt of haematopoietic cytokines within 10 days of study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01105403

Department of Internal Medicine V
Heidelberg, Germany, 69115
Sponsors and Collaborators
Polyphor Ltd.
Principal Investigator: Hartmut Goldschmidt, MD Heidelberg University

Responsible Party: Polyphor Ltd. Identifier: NCT01105403     History of Changes
Other Study ID Numbers: POL-2
First Posted: April 16, 2010    Key Record Dates
Last Update Posted: April 23, 2014
Last Verified: April 2014

Keywords provided by Polyphor Ltd.:
Hematopoietic stem cells
Autologous transplantation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases